These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 21937059)

  • 21. Bipolar I and II disorder residual symptoms: oxcarbazepine and carbamazepine as add-on treatment to lithium in a double-blind, randomized trial.
    Juruena MF; Ottoni GL; Machado-Vieira R; Carneiro RM; Weingarthner N; Marquardt AR; Fleig SS; Broilo L; Busnello EA
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Feb; 33(1):94-9. PubMed ID: 19007842
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relative effectiveness of adjunctive risperidone on manic and depressive symptoms in mixed mania.
    Singh V; Bowden CL; Mintz J
    Int Clin Psychopharmacol; 2013 Mar; 28(2):91-5. PubMed ID: 23238761
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of Brain Functional Changes in High-Frequency Repetitive Transcranial Magnetic Stimulation in Treatment-Resistant Depression.
    Ozekes S; Erguzel T; Sayar GH; Tarhan N
    Clin EEG Neurosci; 2014 Oct; 45(4):257-261. PubMed ID: 24733717
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Frontal and rostral anterior cingulate (rACC) theta EEG in depression: implications for treatment outcome?
    Arns M; Etkin A; Hegerl U; Williams LM; DeBattista C; Palmer DM; Fitzgerald PB; Harris A; deBeuss R; Gordon E
    Eur Neuropsychopharmacol; 2015 Aug; 25(8):1190-200. PubMed ID: 25936227
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Open-label aripiprazole in the treatment of acute bipolar depression: a prospective pilot trial.
    McElroy SL; Suppes T; Frye MA; Altshuler LL; Stanford K; Martens B; Leverich GS; Post RM; Keck PE
    J Affect Disord; 2007 Aug; 101(1-3):275-81. PubMed ID: 17229469
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extended-release quetiapine as monotherapy for the treatment of adults with acute mania: a randomized, double-blind, 3-week trial.
    Cutler AJ; Datto C; Nordenhem A; Minkwitz M; Acevedo L; Darko D
    Clin Ther; 2011 Nov; 33(11):1643-58. PubMed ID: 22054797
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A prospective, open-label study of Aripiprazole mono- and adjunctive treatment in acute bipolar depression.
    Dunn RT; Stan VA; Chriki LS; Filkowski MM; Ghaemi SN
    J Affect Disord; 2008 Sep; 110(1-2):70-4. PubMed ID: 18272230
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Why do clinicians maintain antidepressants in some patients with acute mania? Hints from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM), a large naturalistic study.
    Rosa AR; Cruz N; Franco C; Haro JM; Bertsch J; Reed C; Aarre TF; Sanchez-Moreno J; Vieta E
    J Clin Psychiatry; 2010 Aug; 71(8):1000-6. PubMed ID: 20361912
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical experience using adjunctive gabapentin in treatment-resistant bipolar mixed states.
    Perugi G; Toni C; Ruffolo G; Sartini S; Simonini E; Akiskal H
    Pharmacopsychiatry; 1999 Jul; 32(4):136-41. PubMed ID: 10505483
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes in brain function (quantitative EEG cordance) during placebo lead-in and treatment outcomes in clinical trials for major depression.
    Hunter AM; Leuchter AF; Morgan ML; Cook IA
    Am J Psychiatry; 2006 Aug; 163(8):1426-32. PubMed ID: 16877657
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I).
    Young AH; McElroy SL; Bauer M; Philips N; Chang W; Olausson B; Paulsson B; Brecher M;
    J Clin Psychiatry; 2010 Feb; 71(2):150-62. PubMed ID: 20122369
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Triacetyluridine (TAU) decreases depressive symptoms and increases brain pH in bipolar patients.
    Jensen JE; Daniels M; Haws C; Bolo NR; Lyoo IK; Yoon SJ; Cohen BM; Stoll AL; Rusche JR; Renshaw PF
    Exp Clin Psychopharmacol; 2008 Jun; 16(3):199-206. PubMed ID: 18540779
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical effect of nemifitide, a novel pentapeptide antidepressant, in the treatment of severely depressed refractory patients.
    Feighner JP; Sverdlov L; Hlavka J; Nicolau G; Cartwright K; Freed JS
    Int Clin Psychopharmacol; 2008 Jan; 23(1):29-35. PubMed ID: 18090505
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Do prefrontal midline electrodes provide unique neurophysiologic information in Major Depressive Disorder?
    Cook IA; Hunter AM; Korb AS; Leuchter AF
    J Psychiatr Res; 2014 Jun; 53():69-75. PubMed ID: 24630467
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A factor analytic study in bipolar depression, and response to lamotrigine.
    Mitchell PB; Hadzi-Pavlovic D; Evoniuk G; Calabrese JR; Bowden CL
    CNS Spectr; 2013 Aug; 18(4):214-24. PubMed ID: 23702258
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An investigation of EEG, genetic and cognitive markers of treatment response to antidepressant medication in patients with major depressive disorder: a pilot study.
    Spronk D; Arns M; Barnett KJ; Cooper NJ; Gordon E
    J Affect Disord; 2011 Jan; 128(1-2):41-8. PubMed ID: 20619899
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rates of remission/euthymia with quetiapine monotherapy compared with placebo in patients with acute mania.
    Ketter TA; Jones M; Paulsson B
    J Affect Disord; 2007; 100 Suppl 1():S45-53. PubMed ID: 17383011
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of switching from mania to depression in a large observational study across Europe (EMBLEM).
    Vieta E; Angst J; Reed C; Bertsch J; Haro JM;
    J Affect Disord; 2009 Nov; 118(1-3):118-23. PubMed ID: 19269690
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neurophysiologic predictors of treatment response to fluoxetine in major depression.
    Cook IA; Leuchter AF; Witte E; Abrams M; Uijtdehaage SH; Stubbeman W; Rosenberg-Thompson S; Anderson-Hanley C; Dunkin JJ
    Psychiatry Res; 1999 Mar; 85(3):263-73. PubMed ID: 10333379
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.